ClearView Radiation Shielding- Vial Shield
Vial infusion of radioisotopes in Theranostics requires shielding the nuclear medicine technologist administering a dose. ClearView Vial Shield can be used for Ac-225 PSMA, I-123 and I-131 mIBG therapies, Lutathera (Lu-177) therapies for Neuroendocrine Tumor Treatment, FDA approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan or 177Lu-PSMA-617) for the treatment of prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). Using lead vial shields has led to incomplete infusion of radionuclides such as Lu-177 which is used to treat Neuroendocrine Tumors and PSMA Therapies.The ClearView Vial Shield provides significant workflow and operational advantages over available products. Lead vial shields are heavy to handle, and being RoHS restricted substance requiring special handling.
The ClearView RS® Vial Shield fits vials up to 30 ml, including those supplied by AAA (manufacturing Lutathera). There have been cases where heavy and opaque lead pigs have not been the most ideal shields for Lutathera infusion. To avoid incomplete infusion and easily monitor the volume of radiopharmaceutical (here Lu177) administered, a clear shield has been developed to house a Lu-177 vial using ClearView Radiation Shielding. This product allows the nuclear medicine technologist to fully administer a dose without any being left in the vial using a significantly lighter shield providing protection for betas and gammas.
Shielding Data
- 99.97% Attenuation for – Lu 177
- 3.6 mm Lead equivalency for Lu 177
- Acrylic housing effectively blocks Beta emissions
Specifications
- Fits upto 30 ml vials
- Weight 7 lbs 4 oz
- Height 6.75’’
- Outer Diameter 4.75’’
- 6 mm thick acrylic
- Removable lid
Material Properties
